
AgeX Therapeutics, Inc. – AMEX:AGE
AgeX Therapeutics stock price monthly change
AgeX Therapeutics stock price quarterly change
AgeX Therapeutics stock price yearly change
AgeX Therapeutics key metrics
Market Cap | 27.75M |
Enterprise value | 31.08M |
P/E | -2.19 |
EV/Sales | 914.25 |
EV/EBITDA | -4.40 |
Price/Sales | 708.34 |
Price/Book | -1.39 |
PEG ratio | 0.10 |
EPS | -14.06 |
Revenue | 116K |
EBITDA | -10.01M |
Income | -20.96M |
Revenue Q/Q | -50% |
Revenue Y/Y | 197.43% |
Profit margin | -30770.59% |
Oper. margin | -20514.71% |
Gross margin | 61.76% |
EBIT margin | -20514.71% |
EBITDA margin | -8636.21% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAgeX Therapeutics stock price history
AgeX Therapeutics stock forecast
AgeX Therapeutics financial statements
Jun 2023 | 9K | -2.66M | -29655.56% |
---|---|---|---|
Sep 2023 | 46K | -5.40M | -11741.3% |
Dec 2023 | 56K | -3.45M | -6171.43% |
Mar 2024 | 5K | -9.43M | -188740% |
Jun 2023 | 12277000 | 34.57M | 281.61% |
---|---|---|---|
Sep 2023 | 12210000 | 39.85M | 326.41% |
Dec 2023 | 11965000 | 6.60M | 55.22% |
Mar 2024 | 10856000 | 15.16M | 139.69% |
Jun 2023 | -2.01M | 0 | 2M |
---|---|---|---|
Sep 2023 | -1.86M | 0 | 2M |
Dec 2023 | -2.05M | 0 | 2M |
Mar 2024 | -1.57M | -14K | 2.72M |
AgeX Therapeutics alternative data
Aug 2023 | 5 |
---|---|
Sep 2023 | 5 |
Oct 2023 | 5 |
Nov 2023 | 5 |
Dec 2023 | 5 |
Jan 2024 | 5 |
Feb 2024 | 5 |
Mar 2024 | 4 |
Apr 2024 | 4 |
May 2024 | 4 |
Jun 2024 | 4 |
Jul 2024 | 4 |
AgeX Therapeutics other data
Period | Buy | Sel |
---|---|---|
Feb 2022 | 308565 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | WEST MICHAEL D officer: Chief Ex.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D officer: Chief Ex.. | Common Stock, $0.0001 par value | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Common Stock, $0.0001 par value | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Common Stock, $0.0001 par value | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Common Stock, $0.0001 par value | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | WEST MICHAEL D director, officer.. | Common Stock, $0.0001 par value | 3,125 | N/A | N/A |
Patent |
---|
Application Filling date: 6 Dec 2021 Issue date: 26 May 2022 |
Application Filling date: 17 Feb 2021 Issue date: 14 Apr 2022 |
Application Filling date: 6 Dec 2021 Issue date: 24 Mar 2022 |
Application Filling date: 6 Dec 2021 Issue date: 24 Mar 2022 |
Application Filling date: 22 Jan 2021 Issue date: 4 Nov 2021 |
Application Filling date: 23 Apr 2019 Issue date: 17 Jun 2021 |
Grant Filling date: 3 Jun 2014 Issue date: 30 Mar 2021 |
Application Filling date: 27 Mar 2020 Issue date: 1 Oct 2020 |
Application Filling date: 27 Mar 2020 Issue date: 1 Oct 2020 |
Application Filling date: 7 Jan 2020 Issue date: 16 Jul 2020 |
Insider | Compensation |
---|---|
Dr. Michael D. West Ph.D. (1953) Founder, Pres, Chief Executive Officer & Director | $561,030 |
Dr. Nafees Naseer Malik M.D. (1977) Chief Operating Officer | $282,270 |
Ms. Eun-Jae Park CPA (1972) Chief Financial Officer | $277,350 |
-
When is AgeX Therapeutics's next earnings date?
Unfortunately, AgeX Therapeutics's (AGE) next earnings date is currently unknown.
-
Does AgeX Therapeutics pay dividends?
No, AgeX Therapeutics does not pay dividends.
-
How much money does AgeX Therapeutics make?
AgeX Therapeutics has a market capitalization of 27.75M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 317.65% to 142K US dollars.
-
What is AgeX Therapeutics's stock symbol?
AgeX Therapeutics, Inc. is traded on the AMEX under the ticker symbol "AGE".
-
What is AgeX Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AgeX Therapeutics?
Shares of AgeX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AgeX Therapeutics's key executives?
AgeX Therapeutics's management team includes the following people:
- Dr. Michael D. West Ph.D. Founder, Pres, Chief Executive Officer & Director(age: 72, pay: $561,030)
- Dr. Nafees Naseer Malik M.D. Chief Operating Officer(age: 48, pay: $282,270)
- Ms. Eun-Jae Park CPA Chief Financial Officer(age: 53, pay: $277,350)
-
Is AgeX Therapeutics founder-led company?
Yes, AgeX Therapeutics is a company led by its founder Dr. Michael D. West Ph.D..
-
How many employees does AgeX Therapeutics have?
As Jul 2024, AgeX Therapeutics employs 4 workers.
-
When AgeX Therapeutics went public?
AgeX Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 29 Nov 2018.
-
What is AgeX Therapeutics's official website?
The official website for AgeX Therapeutics is agexinc.com.
-
Where are AgeX Therapeutics's headquarters?
AgeX Therapeutics is headquartered at 1101 Marina Village Parkway, Alameda, CA.
-
How can i contact AgeX Therapeutics?
AgeX Therapeutics's mailing address is 1101 Marina Village Parkway, Alameda, CA and company can be reached via phone at +51 06718370.
AgeX Therapeutics company profile:

AgeX Therapeutics, Inc.
agexinc.comAMEX
4
Biotechnology
Healthcare
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Alameda, CA 94501
CIK: 0001708599
ISIN: US00848H1086
CUSIP: 00848H108